Cagrilintide + Semaglutide vs Tirzepatide: What’s the Difference?
The main difference between Cagrilintide + Semaglutide and Tirzepatide is mechanism: Cagrilintide + Semaglutide is studied for amylin + glp-1 combination weight-loss research — Semaglutide activates GLP-1 receptors for satiety and glucose control; Cagrilintide engages amylin receptors to slow gastric emptying and reduce food intake. Tirzepatide is studied for dual-agonist weight loss research — Dual GLP-1 + GIP receptor agonist.
GLP-1 + amylin combination vs GLP-1/GIP dual.
Key differences between Cagrilintide + Semaglutide and Tirzepatide
- •Mechanism: Cagrilintide + Semaglutide — Semaglutide activates GLP-1 receptors for satiety and glucose control; Cagrilintide engages amylin receptors to slow gastric emptying and reduce food intake. Tirzepatide — Dual GLP-1 + GIP receptor agonist.
- •Primary research focus: Cagrilintide + Semaglutide is studied for amylin + glp-1 combination weight-loss research; Tirzepatide is studied for dual-agonist weight loss research.
- •Overlap: the two compounds share weight loss & metabolism.
- •Discussion context: Cagrilintide + Semaglutide is most often discussed alongside amylin + glp-1 combination weight-loss research, while Tirzepatide centres on dual-agonist weight loss research.
| Attribute | Cagrilintide + Semaglutide CagriSema | Tirzepatide Dual GIP/GLP-1 receptor agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Amylin + GLP-1 combination weight-loss research | Dual-agonist weight loss research |
| Mechanism of action | Semaglutide activates GLP-1 receptors for satiety and glucose control; Cagrilintide engages amylin receptors to slow gastric emptying and reduce food intake. | Dual GLP-1 + GIP receptor agonist. Stronger appetite suppression and glycemic control than single agonists. |
| Human research | Not catalogued | Strong |
| Animal research | Not catalogued | Strong |
| Mechanistic research | Not catalogued | Established |
| Study cadence cited | — | Once weekly, subcutaneous |
| In plain English | Two appetite-control switches in one protocol — GLP-1 for satiety, amylin for slower gastric emptying. | Tirzepatide is like Semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies. |
| How it works | Semaglutide activates GLP-1 receptors for satiety and glucose control; Cagrilintide engages amylin receptors to slow gastric emptying and reduce food intake. | Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying. |
| Researchers study | Obesity, weight maintenance, and combination metabolic therapy. | Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes. |
| Internet discussion | Discussed as the GLP-1/amylin answer to Tirzepatide's GLP-1/GIP combination. | Often described as 'Dr. Jay’s Sema on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules. |
Mechanism and research evidence, side by side
How Cagrilintide + Semaglutide and Tirzepatide differ at the receptor level, and how much published research currently supports each. Evidence ratings describe the depth of publicly available literature — they are not claims of safety or effectiveness.
Tirzepatide
Dual GLP-1 + GIP receptor agonist. Stronger appetite suppression and glycemic control than single agonists.
- Incretin and appetite-regulating receptors
- Slowed gastric emptying and altered satiety signalling
- Energy-balance and glycaemic research endpoints
- Human research
- Strong
- Animal research
- Strong
- Mechanistic research
- Established
Weight loss (typically more aggressive than semaglutide), Type 2 diabetes
Cagrilintide + Semaglutide
Amylin + GLP-1 combination weight-loss research
Two appetite-control switches in one protocol — GLP-1 for satiety, amylin for slower gastric emptying.
Semaglutide activates GLP-1 receptors for satiety and glucose control; Cagrilintide engages amylin receptors to slow gastric emptying and reduce food intake.
Obesity, weight maintenance, and combination metabolic therapy.
Discussed as the GLP-1/amylin answer to Tirzepatide's GLP-1/GIP combination.
Cagrilintide + Semaglutide (CagriSema) is the leading GLP-1 + amylin research combination for weight loss.
Tirzepatide
Dual-agonist weight loss research
Tirzepatide is like Semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies.
Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying.
Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes.
Often described as 'Dr. Jay’s Sema on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules.
Tirzepatide is a dual GLP-1/GIP agonist with strong clinical data for weight reduction and glycemic control.